BAYRY Stock Recent News

Bayer AG [BAYZF] Q1 2024 Earnings Conference Call May 14, 2024 8:00 AM ET Company Participants Bill Anderson - Chairman & CEO Wolfgang Nickl - CFO Julio Triana - President, Consumer Health Division Stefan Oelrich - President, Pharmaceuticals Division Rodrigo Santos - President, Crop Science Division Jost Reinhard - IR Conference Call Participants Emily Field - Barclays Vincent Andrews - Morgan Stanley Peter Verdult - Citibank Richard Vosser - J.P. Morgan Joel Jackson - BMO Capital Markets Florent Cespedes - Bernstein Sachin Jain - Bank of America Jost Reinhard Good afternoon, good morning to everybody.

Bayer's (BAYRY) Q1 earnings and sales decline year over year due to a fall in volumes for non-glyphosate-based herbicides and lower prices for glyphosate-based products in the Crop Science division.

Bayer on Tuesday reported a 1.3% decline in adjusted earnings in the first quarter, beating analysts' forecasts on better-than-expected performance at its prescription drugs and agriculture divisions.

CHICAGO--(BUSINESS WIRE)--Leading real-time supply chain visibility provider FourKites today announced that it will join Bayer and Graphic Packaging International in two separate tracks at the upcoming Gartner Supply Chain Symposium/Xpo™ 2024, where the world's chief supply chain officers (CSCOs), experts and supply chain leaders meet to share insights and strategies that can drive tangible impact in their organizations. FourKites founder and CEO Mathew Elenjickal will join Bayer's Global Direc.

Bayer's patent covering its best-selling blood thinner Xarelto is invalid, London's High Court ruled on Friday in a blow to the German drugmaker.

A Missouri judge slashed a $1.56 billion verdict against Bayer to $611 million for three people who claimed its Roundup weed killer caused their cancer, by reducing punitive damages. Bayer said on Friday it is appealing.

M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot and active area for deal volume, with global sales projected to reach $375 billion by 2027. Today, we profile two smaller oncology names that appear to be logical acquisitions for larger concerns that want to expand their oncology footprints.

Bayer (BAYRY) relies on pipeline candidate elinzanetant and key drugs, Nubeqa and Kerendia, to drive growth amid pipeline and regulatory setbacks.

Bayer on Thursday predicted at least $1 billion in 2024 sales for prostate cancer drug Nubeqa, which is playing a bigger role for the drugmaker's growth prospects after the failure of a promising anti-blood-clotting therapy.

Bayer's (BAYRY) pipeline candidate, elinzanetant, achieves primary and secondary goals in late-stage OASIS 3 study supporting submissions for marketing authorization.